Literature DB >> 9845542

Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.

N Takahashi1, I Miura, K Saitoh, A B Miura.   

Abstract

Chronic myeloid leukemia (CML) is thought to arise from a pluripotent hematopoietic stem cell that has undergone a reciprocal translocation between the BCR gene on chromosome 22 and the ABL proto-oncogene on chromosome 9. This rearrangement results in a shortened chromosome 22, designated the Philadelphia (Ph) chromosome. The Ph chromosome has been found in cells from all hematopoietic lineages except mature T lymphocytes. To examine this issue, we combined fluorescence-activated cell sorting (FACS) and fluorescence in situ hybridization (FISH) to study lineage involvement of mature cells and stem cells in 12 patients with CML in the chronic phase. We found Ph chromosomes in myeloid cells and most B lymphocytes (CD19(+)) but not in mature T cells (CD3(+)) or natural killer (NK) cells (CD3(-)56(+)). Moreover, evidence of BCR/ABL fusion was found in pluripotent stem cells (CD34(+)Thy-1(+)), B-progenitor cells (CD34(+)CD19(+)), T/NK progenitor cells (CD34(+)CD7(+) cells), and T progenitor cells (CD34(+)CD7(+)CD5(+)) with a frequency equal to that in all CD34(+) cells isolated by FACS from bone marrow cells. T lymphocytes showed a marked decrease in Ph+ cells between progenitor cells and mature cells. Moreover, the ratios of Ph+ to Ph- cells in mature T cells and NK cells were below background levels, whereas Ph+ B lymphocytes also decreased during their maturation. These data suggest that Ph+ lymphocytes are eliminated during differentiation. In contrast to FISH of blood and bone marrow, which gives information principally about mature cells, the technique of "sorter FISH (FACS + FISH)" provides a powerful tool to explore the cytogenetic changes in immature cell populations of stem cell diseases based on immunophenotypes. Further clarification of genetic changes in stem cells could be achieved by using sorter FISH with monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845542

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.

Authors:  Naoto Takahashi; Yoshihiro Kameoka; Hiroyuki Tagawa; Hirobumi Saitoh; Tomoko Yoshioka; Naohito Fujishima; Atsushi Kitabayashi; Kaoru Takahashi; Makoto Hirokawa; Kenichi Sawada
Journal:  Int J Hematol       Date:  2010-09-14       Impact factor: 2.490

Review 2.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 3.  Aging, B lymphopoiesis, and patterns of leukemogenesis.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Kenneth Dorshkind
Journal:  Exp Gerontol       Date:  2006-12-20       Impact factor: 4.032

4.  Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Jami McLaughlin; Kenneth Dorshkind
Journal:  Blood       Date:  2007-06-06       Impact factor: 22.113

5.  Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

Authors:  Hugues de Lavallade; Ahmad Khoder; Melanie Hart; Anushruti Sarvaria; Takuya Sekine; Abdullah Alsuliman; Stephan Mielke; Alexandra Bazeos; Kate Stringaris; Sara Ali; Dragana Milojkovic; Letizia Foroni; Aristeidis Chaidos; Nichola Cooper; Ian Gabriel; Jane Apperley; Sarah Belsey; Robert J Flanagan; John Goldman; Elizabeth J Shpall; Peter Kelleher; David Marin; Katayoun Rezvani
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

6.  Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.

Authors:  Naoto Takahashi; Ikuo Miura; Yoshimi Kobayashi; Masaaki Kume; Tomoko Yoshioka; Wataru Otane; Kaori Ohtsubo; Kaoru Takahashi; Atsushi Kitabayashi; Yoshinari Kawabata; Makoto Hirokawa; Hirokazu Nishijima; Ryo Ichinohasama; John Decoteau; Akira B Miura; Ken-Ichi Sawada
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

7.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 8.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

9.  Targeting the Warburg effect for leukemia therapy: Magnitude matters.

Authors:  Ying-Hua Wang; David T Scadden
Journal:  Mol Cell Oncol       Date:  2015-05-06

10.  CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Authors:  Irene Dogliotti; Carmen Fava; Anna Serra; Enrico Gottardi; Filomena Daraio; Francesca Carnuccio; Emilia Giugliano; Monica Bocchia; Giuseppe Saglio; Giovanna Rege-Cambrin
Journal:  Stem Cell Investig       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.